Taconic Insights

Biopharmaceutical Trends and R&D

Taconic Biosciences has remained one of the world's leading providers of research models and services for over 60 years through our commitment to anticipating clients’ needs and industry trends. One of the key trends of the past ten years involves our clients’ need to strategically outsource functional areas of their R&D programs. When companies, academic institutions, government agencies and others outsource certain R&D functions they begin to rely on their collaborators, such as Taconic, to keep them apprised of emerging science and technologies in our specific areas of expertise.
In this spirit of collaboration, we present "Taconic Insights", a new section of our website dedicated to educating the industry on key scientific and technological trends impacting biopharmaceutical R&D. Here you will find the latest insights Taconic can provide in the form of articles, white papers, videos, webinars, presentations, and other media.

C57BL/6 DIO 101: Best Practices for Diet Induced Obesity in Mice

A DIO (diet induced obese) mouse is a C57BL/6 - "Black 6" - mouse which has been made obese through conditioning with a special diet. These diets tend to be high in fat, however there are sometimes other modifications made such as added sugar and there are varying types of fat used to create the diet. View the Taconic Biosciences Webinar: DIO 101: Diet-induced Obesity in Mice...

Read More

Are Humanized Mice the Future of Oncology Models?

Oncologists are up against the limits of cell cultures and xenografts in applied research. Are humanized mice the solution? In an article discussing the challenge of tumor heterogeneity, Drug Discovery News (DDN) laid out several factors which contribute to heterogeneity and which complicate the clinical presentation of tumors, but which are not well modeled in cell culture: Genetically diverse subclonal populations, both within a tumor and across...

Read More

The Dirty Future of Immunology Animal Models

When discrepancies in immune response arise between animal models and humans, some investigators are quick to question the adequacy of laboratory mice as a proxy for human subjects. Two collaborative studies, published in Nature and Cell Host & Microbe, suggest that animal model microbiome and health standards are key to interpreting these discrepancies - and that mice with more extensive history of pathogen exposure may better model...

Read More

Choosing a Health Standard for Your Model

Taconic produces rodent models at several different health standards. How do you know which health designation to choose when ordering animals? Taconic rodent models are available at multiple health standards, enabling researchers to choose the most appropriate model for their studies. These five health standards are defined by the progressive exclusion of foreign organisms. The general health standard for most immunocompetent models is Murine Pathogen Free™ (MPF™)....

Read More

Preclinical Immuno-Oncology Animal Models

Immuno-oncology - triggering a patient's own immune system to attack their cancer - is sweeping through all levels of oncology research, from academia to biotech and pharma. Silicon Valley mogul Sean Parker, co-founder of Napster and first president of Facebook, pledged $250 million to set up the Parker Institute for Cancer Immunotherapy. Pharma and biotech are betting big on immunotherapy also, with significant resources devoted to immunotherapy...

Read More

Patient-derived Xenografts of Hematological Malignancies Webinar Review

Dr. Julia Schueler of Oncotest presented a webinar exploring her work with patient-derived xenografts (PDX) of hematological malignancies as model systems for drug development and tumor biology research. PDX models of hematological origin provide the same advantages as solid tumor PDX models, such as preserving tumor heterogeneity and the treatment sensitivity profile of the donor patient. View the Taconic Biosciences Webinar: Patient-Derived Xenografts of Hematological Malignancies For...

Read More

Review: Humanized Mouse Model Research Symposia

Humanized mouse models are critical tools for basic research, modeling of certain human-specific infectious diseases, efficacy testing of immunotherapy approaches, and safety assessment for large molecule therapeutics. Taconic Biosciences recently hosted the symposium series "Advanced Preclinical Models for Immuno-oncology and Infectious Disease" in several European cities, which focused on the latest research applications of human immune system engrafted mice and the introduction of next generation models. International...

Read More

Production of Germ-Free Mice: Then and Now

On September 26, 1949, Life Magazine showed the world "a strange, new sterile laboratory at Notre Dame", where animal care technicians in diving suits submerged themselves in germicidal tanks, and animals were raised in sealed environments. Scientists were curious whether germ-free organisms would live longer, and planned to study cancer, heart disease, tooth decay, and more. That first germ-free laboratory was a marvel, but it was beyond...

Read More

Patient-Derived Xenografts Q&A with Dr. Els Hermans

Dr. Els Hermans, whose work on the Trace platform at KU Leuven is streamlining the oncology R&D pipeline, presented a webinar focused on the application of patient-derived xenograft models (PDX) in translational cancer research. Her presentation on use of PDX models to close the gap between pre-clinical and clinical trials, and their application in personalized medicine, generated substantial interest from the research community. View the Taconic Biosciences...

Read More

Quality and Study Design Considerations for Carcinogenicity Testing with the rasH2

75% of mouse carcinogenicity studies submitted to the FDA utilize the rasH2 mouse model (Tg.rasH2), a model accepted by the FDA as an alternative to the two-year in vivo bioassay for predicting human carcinogenic risk. In an evolving carcinogenicity testing landscape, with the utility of two-year rat bioassay under re-consideration and changes under consideration to the ICH guidelines for carcinogenic risk assessment, several key questions come to...

Read More